Breaking News Instant updates and real-time market news.

LPCN

Lipocine

$4.60

-0.82 (-15.13%)

13:06
10/13/16
10/13
13:06
10/13/16
13:06

Lipocine drops after Clarus provides view on patent case against company

Shares of Lipocine (LPCN), an oral drug delivery technology company, are dropping after Clarus Therapeutics commented on its patent infringement lawsuit against Lipocine. WHAT'S NEW: On October 7, Lipocine announced that U.S. District Court in Delaware granted its motion to dismiss a lawsuit filed by Clarus Therapeutics. Clarus claimed that LPCN 1021 infringed Clarus' patent. LPCN 1021 is Lipocine's oral testosterone product candidate for testosterone replacement therapy, or TRT, in adult males for conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism. "We are pleased that the court has dismissed this lawsuit. Going forward, we will continue to aggressively defend our intellectual property," said Dr. Mahesh Patel, President and CEO of Lipocine. WHAT'S NOTABLE: Before the opening of trading this morning, Clarus Therapeutics commented on the prior ruling, noting that the court found that there was not an immediate reason to hear the case given Lipocine's failure to receive FDA market approval for LPCN 1021. Importantly, the decision was made without ruling on the validity of Clarus's U.S. Patent 8,828,428 and other merits of the case. Clarus CEO Dr. Robert Dudley said, "We remain strong in our belief that LPCN 1021 infringes Clarus's '428 patent and it is particularly noteworthy that the court did not rule on this central fact. If LPCN 1021 were to be approved by the FDA, our plan would be to vigorously pursue all avenues to keep Lipocine's LPCN 1021 from entering the market and protect the intellectual property, accompanying financial investment and years of work we have invested in JATENZO -- our oral TRT product." ANALYST VIEWS: Earlier this week, Canaccord analyst John Newman raised his price target on Lipocine to $15 from $6 as he said at the time that believes its oral testosterone product has better safety and convenience versus currently marketed gels and injectables. The analyst sees rapid market share gains and a 20% market share by 2024. Newman reiterated his Buy rating on Lipocine shares. Additionally, on October 7 H.C. Wainwright analyst Corey Davis started Lipocine with a Buy rating and $25 price target. PRICE ACTION: Shares of Lipocine are lower by 35c, or 7.6%, to $4.25 in afternoon trading.

LPCN Lipocine
$4.60

-0.82 (-15.13%)

06/30/16
ROTH
06/30/16
NO CHANGE
Target $30
ROTH
Buy
Lipocine price target lowered to $30 from $40 at Roth Capital
Roth Capital analyst Michael Higgins lowered his price target for Lipocine to $30 from $40 after the FDA issued a Complete Response Letter on Lipocine's oral testosterone product, LPCN 1021, citing "deficiencies related to the dosing algorithm." Roth Capital has a Buy rating on the shares.
10/07/16
HCWC
10/07/16
INITIATION
Target $25
HCWC
Buy
Lipocine initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Lipocine with a Buy rating and $25 price target.
10/11/16
ADAM
10/11/16
NO CHANGE
Target $15
ADAM
Buy
Lipocine price target raised to $15 from $6 at Canaccord
Canaccord analyst John Newman raised his price target on Lipocine to $15 from $6 as he believes its oral testosterone product has better safety and convenience versus currently marketed gels and injectables. The analyst sees rapid market share gains and a 20% market share by 2024. Newman reiterated his Buy rating on Lipocine shares.

TODAY'S FREE FLY STORIES

BABA

Alibaba

$180.07

0.09 (0.05%)

, AAPL

Apple

$158.73

0.06 (0.04%)

08:40
09/20/17
09/20
08:40
09/20/17
08:40
Conference/Events
Bloomberg to hold a forum »

Global Business Forum is…

BABA

Alibaba

$180.07

0.09 (0.05%)

AAPL

Apple

$158.73

0.06 (0.04%)

MA

MasterCard

$142.49

1.09 (0.77%)

UL

Unilever; also tag UN

$59.14

-0.09 (-0.15%)

PEP

PepsiCo

$114.49

-0.5 (-0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 04

    Oct

  • 22

    Oct

CSOD

Cornerstone OnDemand

$39.71

-0.61 (-1.51%)

08:40
09/20/17
09/20
08:40
09/20/17
08:40
Recommendations
Cornerstone OnDemand analyst commentary  »

Cornerstone OnDemand…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

GIS

General Mills

08:39
09/20/17
09/20
08:39
09/20/17
08:39
Hot Stocks
General Mills says expects margin headwinds to lessen during remainder of FY18 »

Says remains on track for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

GM

General Motors

$38.70

0.11 (0.29%)

08:39
09/20/17
09/20
08:39
09/20/17
08:39
Recommendations
General Motors analyst commentary  »

Citi makes case for GM…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGI

Celadon Group

$6.50

-0.05 (-0.76%)

08:38
09/20/17
09/20
08:38
09/20/17
08:38
Hot Stocks
Celadon Group closing its truck driving academy »

Celadon Trucking will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALIOF

Actelion

08:35
09/20/17
09/20
08:35
09/20/17
08:35
Conference/Events
Actelion has a conference call hosted by JPMorgan »

JPMorgan Analyst Gordon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

08:33
09/20/17
09/20
08:33
09/20/17
08:33
Recommendations
Bed Bath & Beyond analyst commentary  »

Bed Bath trends getting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMP

Ameriprise

$141.23

0.37 (0.26%)

08:33
09/20/17
09/20
08:33
09/20/17
08:33
Hot Stocks
Columbia Threadneedle Investments to acquire Lionstone Investments »

Columbia Threadneedle…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEET

Meet Group

$3.84

-0.09 (-2.29%)

08:33
09/20/17
09/20
08:33
09/20/17
08:33
Hot Stocks
Meet Group to acquire social dating app LOVOO for $70M in cash »

The Meet Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECL

Ecolab

$130.74

0.21 (0.16%)

08:31
09/20/17
09/20
08:31
09/20/17
08:31
Hot Stocks
Nalco Champion announces price increase for customers in all segments »

Nalco Champion, an Ecolab…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SR

Spire

$75.35

-0.05 (-0.07%)

, MC

Moelis

$41.35

0.6 (1.47%)

08:31
09/20/17
09/20
08:31
09/20/17
08:31
Conference/Events
American Gas Association to hold a forum »

2017 Mini-Forum for the…

SR

Spire

$75.35

-0.05 (-0.07%)

MC

Moelis

$41.35

0.6 (1.47%)

ATO

Atmos Energy

$85.93

-0.57 (-0.66%)

CPK

Chesapeake Utilities

$77.40

-1.65 (-2.09%)

ED

Consolidated Edison

$83.41

-0.16 (-0.19%)

ES

Eversource

$61.77

0.08 (0.13%)

NI

NiSource

$26.40

-0.14 (-0.53%)

NWN

Northwest Natural Gas

$65.85

-0.3 (-0.45%)

OGS

ONE Gas

$74.60

-0.11 (-0.15%)

SJI

South Jersey Industries

$35.14

-0.28 (-0.79%)

UGI

UGI Corporation

$47.74

-0.17 (-0.35%)

VVC

Vectren

$66.00

-0.35 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 25

    Sep

  • 22

    Oct

  • 31

    Oct

  • 05

    Nov

SCVL

Shoe Carnival

08:31
09/20/17
09/20
08:31
09/20/17
08:31
Upgrade
Shoe Carnival rating change  »

Shoe Carnival upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

KSS

Kohl's

$45.38

0.49 (1.09%)

, AMZN

Amazon.com

$969.86

-4.33 (-0.44%)

08:30
09/20/17
09/20
08:30
09/20/17
08:30
Recommendations
Kohl's, Amazon.com analyst commentary  »

Citi likes Kohl's…

KSS

Kohl's

$45.38

0.49 (1.09%)

AMZN

Amazon.com

$969.86

-4.33 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 09

    Nov

MORE

Monogram Residential Trust

08:30
09/20/17
09/20
08:30
09/20/17
08:30
Options
One option delisting on September 20th »

Option delistings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUVA

NuVasive

$53.54

-4.26 (-7.37%)

08:29
09/20/17
09/20
08:29
09/20/17
08:29
Recommendations
NuVasive analyst commentary  »

NuVasive price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GEMP

Gemphire Therapeutics

$9.65

0.54 (5.93%)

08:29
09/20/17
09/20
08:29
09/20/17
08:29
Recommendations
Gemphire Therapeutics analyst commentary  »

Gemphire data support…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

RDUS

Radius Health

$33.99

0.28 (0.83%)

08:26
09/20/17
09/20
08:26
09/20/17
08:26
Conference/Events
Radius Health has a conference call hosted by JPMorgan »

JPMorgan Analyst Fye will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

JAZZ

Jazz Pharmaceuticals

$151.18

-1.47 (-0.96%)

08:25
09/20/17
09/20
08:25
09/20/17
08:25
Recommendations
Jazz Pharmaceuticals analyst commentary  »

Doctor feedback on Jazz…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$75.04

-0.96 (-1.26%)

, IONS

Ionis Pharmaceuticals

$59.07

-0.5 (-0.84%)

08:24
09/20/17
09/20
08:24
09/20/17
08:24
Recommendations
Alnylam, Ionis Pharmaceuticals analyst commentary  »

Alnylam study 'hits…

ALNY

Alnylam

$75.04

-0.96 (-1.26%)

IONS

Ionis Pharmaceuticals

$59.07

-0.5 (-0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

NWBO

Northwest Biotherapeutics

$0.22

0.004 (1.86%)

08:24
09/20/17
09/20
08:24
09/20/17
08:24
Syndicate
Northwest Biotherapeutics raises $1.75M in a registered direct offering »

Northwest Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:23
09/20/17
09/20
08:23
09/20/17
08:23
Conference/Events
Federal Reserve Chairperson Yellen holds a press conference »

Following a quarterly…

LB

L Brands

$39.23

-0.75 (-1.88%)

08:23
09/20/17
09/20
08:23
09/20/17
08:23
Downgrade
L Brands rating change  »

L Brands downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPCN

Lipocine

$3.93

-0.05 (-1.26%)

08:22
09/20/17
09/20
08:22
09/20/17
08:22
Hot Stocks
Lipocine announces FDA advisory committee meeting for Tlando »

Lipocine announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

$DJT

DJ Transportation Average

08:22
09/20/17
09/20
08:22
09/20/17
08:22
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJU

DJ Utility Average

08:21
09/20/17
09/20
08:21
09/20/17
08:21
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.